Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The potential of a selective anxiolytic afobazole in clinical practice].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[Transitional cognitive syndrome: Reconsidered classification of cognitive disorders].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[Rapidly progressive cognitive impairment as a single clinical manifestation of anti-NMDA receptor encephalitis].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[New Opportunities in the Treatment of Moderate Cognitive Impairment: Results of the Millennium Study in Real Clinical Practice].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[Clinical and kinematic analysis of swimming disorders in Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[The patient pathway in the diagnosis and treatment of mild cognitive impairment and new therapeutic opportunities. Resolution of the Expert Council (Moscow, April 21, 2025)].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025

Related Experiment Video

Updated: May 15, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

[Dementia with Lewy bodies].

O S Levin, E E Vasenina, M A Anikina

    Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
    |December 20, 2012
    PubMed
    Summary

    Dementia with Lewy bodies (DLB) is a common dementia type. This review covers DLB

    Area of Science:

    • Neurology
    • Neuroscience
    • Geriatrics

    Background:

    • Dementia with Lewy bodies (DLB) accounts for 10% of dementia cases.
    • Review of the nosological status of DLB and its link to Parkinson's disease.
    • Historical context of DLB classification and diagnosis.

    Discussion:

    • Current clinical presentations, diagnostic criteria, and treatment strategies for DLB.
    • Approaches to DLB diagnosis and coding according to ICD-10.
    • Analysis of pharmacological interventions for DLB management.

    Key Insights:

    • DLB diagnosis requires careful consideration of clinical features and disease progression.
    • Understanding the DLB-Parkinson's disease relationship is crucial for accurate diagnosis.
    • Evidence-based treatment strategies involve a combination of symptomatic and disease-modifying therapies.

    More Related Videos

    Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
    07:26

    Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

    Published on: September 26, 2019

    Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
    08:29

    Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

    Published on: December 18, 2016

    Related Experiment Videos

    Last Updated: May 15, 2026

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
    12:28

    Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

    Published on: June 3, 2020

    Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
    07:26

    Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

    Published on: September 26, 2019

    Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
    08:29

    Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

    Published on: December 18, 2016

    Outlook:

    • Future research directions in DLB pathogenesis and therapeutic targets.
    • Improving diagnostic accuracy and early detection of DLB.
    • Development of novel treatment approaches to enhance quality of life for DLB patients.